MENU MENU

Letter from our CEO on ASN 2020 Kidney Week Reimagined

Read More

Explore Deeply. Uncover the Possibilities.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

Illuminating Possibilities. Charting Pathways.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

Expanding Possibilities.Building Hope.

Pioneering innovative therapeutic options
for patients who need them the most.

Learn More

We create first-in-class medicines to treat chronic and life-threatening conditions such as anemia, idiopathic pulmonary fibrosis, and pancreatic cancer.

Pipeline

We are developing products with the potential to change lives.

Clinical Trials

We are dedicated to responsibly developing groundbreaking therapies for serious and life-threatening diseases.

FibroGen China

We have taken an unprecedented approach to introducing world-class innovations in China.

Press Releases

FibroGen Advances Phase 3 Clinical Development of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis with Initiation of ZEPHYRUS-2

FibroGen Provides Regulatory Update on Roxadustat

FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting

FibroGen Announces Retirement of K. Peony Yu, M.D., and Appointment of Mark Eisner, M.D., M.P.H. as Chief Medical Officer

Astellas Receives Approval of EVRENZO® (roxadustat) in Japan for the Treatment of Anemia of Chronic Kidney Disease in Adult Patients Not on Dialysis
View All

FG Culture

“Being surrounded by so many intelligent, kind, and professional people makes FibroGen a wonderful place to work.”

David Gervasi
Associate Scientist II, Cell Biology

Contact Our Company

We are growing a dedicated team committed to innovation and helping patients worldwide.

Contact Us